Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou, E. Sagiadinou Duration: 40 mins Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Find attached the slides of PeerVoice seminar, presented by Prof Mohty  Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Dr Valera. Duration: 40 mins

Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Valera, Dr Tsokanas Duration: 40 mins These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas 

Find attached the presentation of Prof. Spyridonidis at 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) that was held on Berlin, 27-30 October 2022

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr. Tsokanas Duration: 20mins Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hemato- logic malignancies. Two CAR T products were recently approved in the United States...

https://doi.org/10.1182/blood.2021013290 Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 45 min Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4...

Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Tsokanas, A. Christopoulou, Dr Valera Duration: 40 mins

Επισυνάπτεται η παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη στην επιστημονική διημερίδα του ΕΟΜ με τίτλο «Βελτιώνοντας τις διαδικασίες και την ποιότητα των μεταμοσχεύσεων στην Ελλάδα», η οποία πραγματοποιήθηκε στις 14 & 15 Οκτωβρίου 2022 στο Μουσείο Μπενάκη Παρουσίαση: Kαθ. Αλέξανδρος Σπυριδωνίδης Συμμετέχοντες: Δρ Λίγκα...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00223-X/fulltext?dgcid=hubspot_update_feature_updates22_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=229262662&_hsenc=p2ANqtz-_4qThtytktyouVD9PQP8m6s2Fw61Pl4L4GAD65juL7jMS0i30Ms-ENPUL-k5yafQMCP8p8BUvXYXbK66-tdjlqjUP42w&utm_content=229205353&utm_source=hs_email The effect of the gut microbiota on patients’ outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host...

Presenter: Prof. Alexandros Spyridonidis 2022_AML_NGS_EAE_.pptx

Background- Therapies beyond hypomethylating agents such as azacitidine are needed in high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents. We therefore aimed to evaluate the safety, tolerability, and preliminary activity...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40mins https://www.nature.com/articles/s41591-022-02017-5

Βρείτε συνημμένη την παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη με θέμα "Chimeric Antigen Receptor-T cells (CART cells)" που πραγματοποιήθηκε στις 24 Σεπτεμβρίου 2022 στην επιστημονική συνάντηση με τίτλο «Βελτιστοποιώντας το παρόν, ανοίγοντας νέους ορίζοντες»  

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Prof. Naveen Pemmaraju, Prof. Alexandros Spyridonidis https://youtu.be/fYF55Yb97gI

This article was authored and presented by Prof. Spyridonidis. Participants: Dr. Liga, Dr. Tsokanas, Dr. Valera  Duration: 40mins In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and...

Participants: Dr Liga, Dr Tsokanas, Dr Valera, Zoi Panagi (Pharmassist) Presenter: Prof. Spyridonidis Duration: 40 mins Therapeutic options for patients with AML relapsing after allogeneic HCT range from chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a 2nd allogeneic HCT. Available...